(ABSI) Absci - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 459m USD | Total Return: 31.9% in 12m

Drug Discovery, AI, Antibodies, Therapeutics
Total Rating 31
Safety 68
Buy Signal -1.10
Biotechnology
Industry Rotation: +3.6
Market Cap: 459M
Avg Turnover: 11.3M USD
ATR: 7.14%
Peers RS (IBD): 15.3
Risk 5d forecast
Volatility98.7%
Rel. Tail Risk-8.76%
Reward TTM
Sharpe Ratio0.62
Alpha-8.93
Character TTM
Beta2.298
Beta Downside3.287
Drawdowns 3y
Max DD66.06%
CAGR/Max DD0.32
EPS (Earnings per Share) EPS (Earnings per Share) of ABSI over the last years for every Quarter: "2021-03": -0.1784, "2021-06": -2.39, "2021-09": -0.33, "2021-12": -0.28, "2022-03": -0.33, "2022-06": -0.32, "2022-09": -0.3, "2022-12": -0.21, "2023-03": -0.26, "2023-06": -0.45, "2023-09": -0.24, "2023-12": -0.25, "2024-03": -0.22, "2024-06": -0.22, "2024-09": -0.2412, "2024-12": -0.25, "2025-03": -0.21, "2025-06": -0.24, "2025-09": -0.2, "2025-12": -0.23, "2026-03": 0,
EPS CAGR: 34.96%
EPS Trend: 61.0%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of ABSI over the last years for every Quarter: 2021-03: 1.063, 2021-06: 0.728, 2021-09: 1.539, 2021-12: 1.452, 2022-03: 0.819, 2022-06: 1.002, 2022-09: 2.369, 2022-12: 1.557, 2023-03: 1.269, 2023-06: 3.367, 2023-09: 0.744, 2023-12: 0.338, 2024-03: 0.898, 2024-06: 1.27, 2024-09: 1.701, 2024-12: 0.665, 2025-03: 1.179, 2025-06: 0.593, 2025-09: 0.378, 2025-12: 0.65, 2026-03: null,
Rev. CAGR: -5.98%
Rev. Trend: -44.5%
Last SUE: -1.30
Qual. Beats: 0
Warnings

Share dilution 31.0% YoY - potential capital distress

Interest Coverage Ratio -596.7 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

volatile

Tailwinds

No distinct edge detected

Description: ABSI Absci

Absci Corporation (ABSI) is a generative AI drug creation company. It integrates AI with wet lab technologies to develop antibody therapeutics.

The companys pipeline includes preclinical programs for inflammatory bowel disease, androgenic alopecia, and oncology. This approach is common in the biotechnology sector, where drug discovery often involves extensive research and development before clinical trials.

Absci has established collaborations with various organizations, including PrecisionLife, Memorial Sloan Kettering Cancer Center, and Oracle Corporation, for joint R&D. These partnerships are critical in the AI drug discovery business model, leveraging diverse expertise and resources.

For more detailed financial and operational insights, ValueRay offers comprehensive analysis.

Headlines to Watch Out For
  • AI drug discovery platform drives collaboration revenue growth
  • Preclinical pipeline success impacts future licensing deals
  • Biopharma partnerships secure funding and development milestones
  • R&D expenses remain a significant cost factor
Piotroski VR‑10 (Strict) 0.0
Net Income: -115.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.43 > 0.02 and ΔFCF/TA -9.39 > 1.0
NWC/Revenue: 4.53k% < 20% (prev 2.32k%; Δ 2.21k% < -1%)
CFO/TA -0.43 > 3% & CFO -92.9m > Net Income -115.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.57 > 1.5 & < 3
Outstanding Shares: last quarter (150.6m) vs 12m ago 31.05% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 1.30% > 50% (prev 2.12%; Δ -0.82% > 0%)
Interest Coverage Ratio: -596.7 > 6 (EBITDA TTM -113.0m / Interest Expense TTM 209k)
Altman Z'' -15.00
A: 0.59 (Total Current Assets 149.6m - Total Current Liabilities 22.8m) / Total Assets 216.3m
B: -2.89 (Retained Earnings -624.8m / Total Assets 216.3m)
C: -0.58 (EBIT TTM -124.7m / Avg Total Assets 215.0m)
D: -23.25 (Book Value of Equity -624.2m / Total Liabilities 26.8m)
Altman-Z'' Score: -33.88 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 2.80m/4.53m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.91 (AQ_t 0.20 / AQ_t-1 0.22)
SGI: 0.62 (Revenue 2.80m / 4.53m)
TATA: -0.10 (NI -115.2m - CFO -92.9m) / TA 216.3m)
Beneish M-Score: cannot calculate (missing components)
What is the price of ABSI shares? As of April 06, 2026, the stock is trading at USD 3.06 with a total of 4,676,279 shares traded.
Over the past week, the price has changed by +10.87%, over one month by +18.15%, over three months by -18.18% and over the past year by +31.90%.
Is ABSI a buy, sell or hold? Absci has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABSI.
  • StrongBuy: 5
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ABSI price?
Analysts Target Price 8 162.4%
Absci (ABSI) - Fundamental Data Overview as of 03 April 2026
P/S = 172.1489
P/B = 2.5443
Revenue TTM = 2.80m USD
EBIT TTM = -124.7m USD
EBITDA TTM = -113.0m USD
Long Term Debt = 65.0k USD (from longTermDebt, two quarters ago)
Short Term Debt = 2.68m USD (from shortTermDebt, last quarter)
Debt = 5.30m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -14.7m USD (from netDebt column, last quarter)
Enterprise Value = 320.1m USD (459.1m + Debt 5.30m - CCE 144.3m)
Interest Coverage Ratio = -596.7 (Ebit TTM -124.7m / Interest Expense TTM 209k)
EV/FCF = -3.40x (Enterprise Value 320.1m / FCF TTM -94.0m)
FCF Yield = -29.38% (FCF TTM -94.0m / Enterprise Value 320.1m)
 FCF Margin = -3.36k% (FCF TTM -94.0m / Revenue TTM 2.80m)
 Net Margin = -4.11k% (Net Income TTM -115.2m / Revenue TTM 2.80m)
 Gross Margin = unknown ((Revenue TTM 2.80m - Cost of Revenue TTM 39.6m) / Revenue TTM)
 Tobins Q-Ratio = 1.48 (Enterprise Value 320.1m / Total Assets 216.3m)
Interest Expense / Debt = 0.55% (Interest Expense 29.0k / Debt 5.30m)
Taxrate = 21.0% (US default 21%)
NOPAT = -98.5m (EBIT -124.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.57 (Total Current Assets 149.6m / Total Current Liabilities 22.8m)
Debt / Equity = 0.03 (Debt 5.30m / totalStockholderEquity, last quarter 189.4m)
 Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -14.7m / EBITDA -113.0m)
 Debt / FCF = 0.16 (negative FCF - burning cash) (Net Debt -14.7m / FCF TTM -94.0m)
 Total Stockholder Equity = 193.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.59% (Net Income -115.2m / Total Assets 216.3m)
RoE = -59.68% (Net Income TTM -115.2m / Total Stockholder Equity 193.0m)
RoCE = -64.60% (EBIT -124.7m / Capital Employed (Equity 193.0m + L.T.Debt 65.0k))
 RoIC = -50.55% (negative operating profit) (NOPAT -98.5m / Invested Capital 194.9m)
 WACC = 13.91% (E(459.1m)/V(464.4m) * Re(14.07%) + D(5.30m)/V(464.4m) * Rd(0.55%) * (1-Tc(0.21)))
Discount Rate = 14.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 27.55%
 [DCF] Fair Price = unknown (Cash Flow -94.0m)
 EPS Correlation: 61.00 | EPS CAGR: 34.96% | SUE: 4.0 | # QB: 1
Revenue Correlation: -44.49 | Revenue CAGR: -5.98% | SUE: -1.30 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.20 | Chg7d=-0.036 | Chg30d=-0.036 | Revisions Net=-2 | Analysts=5
EPS current Year (2026-12-31): EPS=-0.79 | Chg7d=-0.087 | Chg30d=-0.087 | Revisions Net=-1 | Growth EPS=+9.9% | Growth Revenue=+185.7%
EPS next Year (2027-12-31): EPS=-0.63 | Chg7d=-0.073 | Chg30d=-0.073 | Revisions Net=+2 | Growth EPS=+20.9% | Growth Revenue=+303.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle